Prepared by: InfiveSource: Insider MonkeyPublished on Infive:
Bio-Techne shareholders approved Merck KGaA’s $73-a-share cash takeover on Sept. 23 but rejected the deal’s executive pay plan. The advisory vote does not affect the payments; Bio-Techne expects closing in late 2026 or early 2027, pending remaining approvals.
The offer values Bio-Techne at about $11.3 billion including debt. The U.S. antitrust waiting period expired Sept. 18; approvals outside the United States remain outstanding.
Bio-Techne shares closed at $72.57 on Sept. 24, 43 cents below the $73 offer price.
